Porter, Andy - University of Aberdeen - School of Medicine, Medical Sciences and Nutrition

研究领域

The central theme in my laboratory is the application of antibody engineering to the solution of both medical and environmental problems. The selection of specific antibody fragments displayed on the surface of large numbers of different filamentous bacteriophage has provided a complementary technology to the well established selection of antibodies from hybridomas. Expression of recombinant antibody structures has been achieved in E. coli, yeast, plant and mammalian cells. Environmental: There is extensive pollution of our environment by organic hydrocarbons and other industrial chemicals. New cost effective methods for the detection and removal of contaminants are required to meet modern safety standards. Antibodies are one of the few molecules that can recognise targets present at concentrations as low as a few parts per trillion. We specialise in the selection of antibody structures specific for small molecular weight targets and have been successful in the generation of highly sensitive diagnostic molecules and have utilised anti-pollutant antibodies in a number of exciting biotechnological projects. Together with colleagues Dr Glover (Molecular and Cell Biology, Aberdeen) and Dr Paton (Plant and Soil Science, Aberdeen) we are now combining our antibody biosensors with bioluminescent whole cell biosensors to generate an environmental diagnostic "tool-kit" suitable for field use. Medical: Using related antibody engineering approaches we are currently involved in projects to develop anti-viral antibody preparations suitable for the topical treatment of disease, identifying novel autoantigens responsible for autoimmune recurrent miscarriage, selecting neutralising toxin specific antibodies and antibodies that will recognise and inhibit cell-cell communication in Gram negative bacteria. Techniques involved include: cloning and selection of antibodies from phage display libraries and hybridomas, recombinant protein expression, protein purification, antibody characterisation by ELISA and BIAcore and protein modelling.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Ubah, OC., Barelle, CJ., Buschhaus, MJ. & Porter, AJ. (2016). 'Phage Display Derived IgNAR V Region Binding Domains for Therapeutic Development'. Current Pharmaceutical Design, vol 22, no. 43, pp. 6519-6526. DOI: [ONLINE] DOI: 10.2174/1381612822666160907091708 Al Qaraghuli, MM., Palliyil, S., Broadbent, G., Cullen, DC., Charlton, KA. & Porter, AJ. (2015). 'Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction'. BMC Biotechnology, vol 15, 99. DOI: [ONLINE] DOI: 10.1186/S12896-015-0217-X [ONLINE] AURA: S12896_015_0217_X.PDF Barelle, C. & Porter, A. (2015). 'VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins'. Antibodies, vol 4, pp. 240-258. DOI: [ONLINE] DOI: 10.3390/ANTIB4030240 [ONLINE] AURA: ANTIBODIES_04_00240.PDF Palliyil, S., Downham, C., Broadbent, I., Charlton, K. & Porter, AJ. (2014). 'High-sensitivity monoclonal antibodies specific for homoserine lactones protect mice from lethal Pseudomonas aeruginosa infections'. Applied and Environmental Microbiology, vol 80, no. 2, pp. 462-469. DOI: [ONLINE] DOI: 10.1128/AEM.02912-13 Kovaleva, M., Ferguson, L., Steven, J., Porter, A. & Barelle, C. (2014). 'Shark variable new antigen receptor biologics: a novel technology platform for therapeutic drug development'. Expert opinion on biological therapy, vol 14, no. 10, pp. 1527-1539. DOI: [ONLINE] DOI: 10.1517/14712598.2014.937701 Wawra, SW., Bain, JM., Durward, E., de Bruijn, I., Minor, KL., Matena, A., Lobach, L., Whisson, SC., Bayer, P., Porter, AJR., Birch, P., Secombes, CJ. & Van West, P. (2012). 'Host-targeting protein 1 (SpHtp1) from the oomycete Saprolegnia parasitica translocates specifically into fish cells in a tyrosine-O-sulphate-dependent manner'. PNAS, vol 109, no. 6, pp. 2096-2101. DOI: [ONLINE] DOI: 10.1073/PNAS.1113775109 Douglass, A., Wallace, K., Koruth, M., Barelle, C., Porter, AJ. & Wright, MC. (2008). 'Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy'. Hepatology International, vol 2, no. 4, pp. 405-15. DOI: [ONLINE] DOI: 10.1007/S12072-008-9093-Y Douglass, A., Wallace, K., Parr, R., Park, J., Durward, E., Broadbent, I., Barelle, C., Porter, AJ. & Wright, MC. (2008). 'Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury'. Journal of Hepatology, vol 49, no. 1, pp. 88-98. DOI: [ONLINE] DOI: 10.1016/J.JHEP.2008.01.032 Milne, SA., Gallacher, S., Cash, P., Lees, DN., Henshilwood, K. & Porter, AJR. (2007). 'A sensitive and reliable reverse transcriptase PCR-enzyme-linked immunosorbent assay for the detection of human pathogenic viruses in bivalve molluscs'. Journal of Food Protection, vol 70, no. 6, pp. 1475-1482. [LINK] HTTP://WWW.INGENTACONNECT.COM/CONTENT/IAFP/JFP/2007/00000070/00000006/ART00022 Shao, C., Secombes, CJ. & Porter, AJR. (2007). 'Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library'. Molecular Immunology, vol 44, no. 4, pp. 656-665. DOI: [ONLINE] DOI: 10.1016/J.MOLIMM.2006.01.010